Table 5 Antiviral activities of target compounds against TMV in vivo at 500 μg/mLa
From: Design, synthesis, and bioactivity of ferulic acid derivatives containing an β-amino alcohol
Compd | Curative activity (%) | Protective activity (%) | Inactivation activity (%) |
|---|---|---|---|
D1 | 56.1 ± 0.8 | 49.9 ± 3.9 | 76.9 ± 1.4 |
D2 | 31.8 ± 4.8 | 41.8 ± 3.5 | 89.1 ± 3.8 |
D3 | 37.5 ± 0.8 | 54.6 ± 2.5 | 93.7 ± 1.9 |
D4 | 38.8 ± 4.5 | 52.6 ± 4.5 | 89.5 ± 1.5 |
D5 | 59.3 ± 0.7 | 59.6 ± 4.9 | 72.9 ± 2.7 |
D6 | 25.1 ± 2.7 | 35.1 ± 0.1 | 73.0 ± 1.7 |
D7 | 31.8 ± 0.7 | 53.1 ± 0.5 | 74.2 ± 2.8 |
D8 | 40.9 ± 2.7 | 47.2 ± 0.8 | 85.2 ± 3.1 |
D9 | 31.5 ± 3.6 | 70.7 ± 5.0 | 84.9 ± 1.9 |
D10 | 38.4 ± 3.3 | 31.4 ± 1.1 | 84.3 ± 4.9 |
D11 | 35.4 ± 1.0 | 34.2 ± 0.1 | 74.1 ± 2.0 |
D12 | 59.8 ± 1.3 | 39.9 ± 1.1 | 61.2 ± 0.3 |
D13 | 53.9 ± 4.7 | 39.8 ± 4.9 | 71.4 ± 0.4 |
D14 | 21.8 ± 4.5 | 74.3 ± 3.7 | 81.2 ± 2.5 |
D15 | 32.3 ± 4.5 | 35.0 ± 2.4 | 82.7 ± 3.3 |
D16 | 22.5 ± 4.8 | 19.0 ± 3.7 | 84.9 ± 3.4 |
D17 | 33.6 ± 2.5 | 43.9 ± 2.2 | 82.5 ± 3.6 |
D18 | 45.5 ± 3.2 | 68.1 ± 3.3 | 84.1 ± 4.5 |
D19 | 34.6 ± 2.1 | 43.7 ± 3.6 | 85.6 ± 4.2 |
D20 | 42.8 ± 0.1 | 51.9 ± 1.6 | 81.8 ± 0.7 |
D21 | 74.0 ± 4.0 | 41.5 ± 2.1 | 60.1 ± 0.1 |
D22 | 20.2 ± 1.7 | 43.6 ± 2.5 | 66.8 ± 0.7 |
D23 | 40.2 ± 3.6 | 54.9 ± 2.7 | 74.5 ± 1.5 |
D24 | 74.1 ± 1.9 | 47.4 ± 2.6 | 74.2 ± 0.8 |
Ribavirin | 44.8 ± 1.2 | 50.0 ± 1.8 | 73.5 ± 1.6 |
Ningnanmycin | 70.0 ± 3.8 | 65.3 ± 2.5 | 93.2 ± 0.5 |